Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyuandan
- Development stage
- Phase 4
- Lead developer
- Beijing Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Shenyuandan is a Traditional Chinese Medicine (TCM) formula, specifically a Yiqi Zhuyu (Qi-supplementing and blood-stasis-resolving) preparation, developed by the Beijing Hospital of Traditional Chinese Medicine. It is administered as capsules and is currently being evaluated in clinical trials to improve coronary microcirculatory dysfunction in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing elective percutaneous coronary intervention (PCI). The formula is intended to be used as an adjunct to standardized care to mitigate perioperative microvascular injury and improve clinical outcomes in cardiovascular patients.
- Brand names
- Shenyuandan
- Other names
- Shenyuandan capsules
02
Targets
Beyond the preview
Go deeper on Shenyuandan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyuandan.